Skip to main content
Feature Story

Circling back to basics

By Chris Cain, Associate Editor

Circling back to basics

Macrocycles have been a hot topic for chemists and pharmacologists alike for the promise they hold of reaching druggable targets that small molecules cannot. Although they are still much more challenging than small molecules to develop, a trio of studies might offer a way forward by proposing new design guidelines,1 identifying protein-protein interfaces to target2 and providing a new method to synthesize cyclic peptides (see Box 1, "Cyclotide synthesis").3

Full Article

Today's Biotech & Pharma News

FDA's History


    Fat chance for cancer cachexia

    With no drugs on the market and a pair of recent Phase III failures in cancer-associated cachexia, companies may consider targeting the cause of the wasting disease rather than its symptoms. Two independent academic teams have now found evidence that browning of white fat is responsible for cachexia in patients with cancer and propose different strategies to block the process.


    AstraZeneca taps the Cambridge wellspring

    AstraZeneca has unveiled plans for its R&D center and global headquarters in Cambridge, U.K. -- the next major step in the pharma's strategy to improve pipeline productivity to help it recover growth and regain ground in scientific leadership. The company hopes to tap into world-class research through partnerships with nearby institutes.


    Corneal perspectives

    Two independent findings could increase the availability of tissue for corneal transplants. A UCSD team has identified key factors needed to culture the limbal stem cells necessary for clear vision. A Harvard team has found a marker for enhanced regenerative potential of limbal stem cells and licensed the antibody to stem cell companies Rheacell and Ticeba.


    Circling back to basics

    Creating potent and orally bioavailable macrocycles is more challenging than developing small molecules, but a trio of studies could close the gap by proposing new design guidelines, identifying protein-protein interfaces to target and providing a new method to synthesize cyclic peptides.


    This Week in Therapeutics

    Preventing tumor regrowth with FASN inhibitors; promoting wound healing with OR2AT4 activators; treating glaucoma with CASP8 inhibitors; and more...


    This Week in Techniques

    A gold plasmonic chip for biomarker discovery and diagnosis of type 1 diabetes; a Camta1-deficient mouse model of ataxia and neurodegenerative disease; a gastric tumor classification system; and more...

Subscribe Now
Free Trial

Preclinical Results

There were no items published for this section in the most recent issue. Click more >> to read previously published items.